ArticleAlcohol, clinical & experimental research2025
Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center.
Article in Alcohol, clinical & experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Exploring Phosphatidylethanol Cutoffs for Self-Reported Unhealthy Alcohol Use: An International Multi-Site Analysis.Alcohol, clinical & experimental research · 2026Article
- The global epidemiology of alcohol-associated liver disease.Hepatology communications · 2026Review
- Alcohol Relapse After Liver Transplantation: Advances in Risk Stratification, Biomarker Integration, and Post-Transplant Care.Gastro hep advances · 2026Review
- Validation of blood phosphatidylethanol as an alcohol consumption biomarker in patients with alcohol use disorder and liver disease at a liver transplant center.Alcohol, clinical & experimental research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhosphatidylethanol (PEth), ethyl glucuronide (EtG), and ethyl sulphate (EtS) are highly sensitive and specific biomarkers of alcohol intake. This study investigated their application and relationship to traditional self-report measures in a mixed cohort of liver disease patients to guide decision making in liver transplant populations.
methodsWe recruited 183 participants (mean age 49.2 years, 62% male), with N = 99 liver disease (88% alcohol-associated liver disease [ALD]), N = 35 alcohol use disorder (AUD), and N = 49 healthy volunteers. Patient-reported alcohol intake and AUDIT score served as references and were compared to traditional biomarkers, PEth and serum EtG/EtS. Receiver operating characteristic (ROC) analysis and a range of biomarker cutoffs were examined to determine optimal test characteristics. A subset of blood samples modified to a standardized hematocrit analyzed the relationship between hematocrit and PEth.
resultsCompared to traditional biomarkers, both PEth and EtG were sensitive and specific for alcohol intake. At the limit of detection (LOD), PEth was 95% sensitive at detecting any drinking. PEth cutoff of 300 μg/L was 86% sensitive and 92% specific for "heavy drinking," and 600 μg/L was 88% sensitive and specific for "very heavy drinking." PEth displayed superior test characteristics (sensitivity, specificity, PPV, NPV, and AUC) to all measured traditional biomarkers over two-day and one-month time frames. A subset of participants suspected of drinking but reporting abstinence had positive PEth tests (35%), suggestive of unreported drinking. PEth was positively correlated with hematocrit (r
conclusionsPEth is clinically useful as an alcohol biomarker in patients with liver disease and is superior to traditional biomarkers, providing good test characteristics for "heavy" and "very heavy" drinking using stepwise cutoffs. PEth detected a subset of patients underreporting their alcohol use, with implications for the management of patients in liver transplant clinics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.